1. Home
  2. PLUS vs MLYS Comparison

PLUS vs MLYS Comparison

Compare PLUS & MLYS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo ePlus inc.

PLUS

ePlus inc.

HOLD

Current Price

$89.27

Market Cap

2.3B

Sector

Technology

ML Signal

HOLD

Logo Mineralys Therapeutics Inc.

MLYS

Mineralys Therapeutics Inc.

HOLD

Current Price

$26.64

Market Cap

2.1B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
PLUS
MLYS
Founded
1990
2019
Country
United States
United States
Employees
N/A
N/A
Industry
Retail: Computer Software & Peripheral Equipment
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.3B
2.1B
IPO Year
1996
2023

Fundamental Metrics

Financial Performance
Metric
PLUS
MLYS
Price
$89.27
$26.64
Analyst Decision
Strong Buy
Analyst Count
0
7
Target Price
N/A
$48.67
AVG Volume (30 Days)
223.7K
1.1M
Earning Date
05-21-2026
05-06-2026
Dividend Yield
1.20%
N/A
EPS Growth
24.20
37.43
EPS
5.03
N/A
Revenue
$2,442,549,000.00
N/A
Revenue This Year
$19.83
N/A
Revenue Next Year
$4.36
N/A
P/E Ratio
$17.26
N/A
Revenue Growth
18.07
N/A
52 Week Low
$62.11
$12.59
52 Week High
$93.98
$47.65

Technical Indicators

Market Signals
Indicator
PLUS
MLYS
Relative Strength Index (RSI) 58.34 45.70
Support Level $84.66 $26.01
Resistance Level $89.44 $31.26
Average True Range (ATR) 3.20 1.23
MACD 0.12 -0.17
Stochastic Oscillator 68.15 13.68

Price Performance

Historical Comparison
PLUS
MLYS

About PLUS ePlus inc.

ePlus Inc is a provider of technology solutions across the IT spectrum, spanning security, cloud, data center, networking, collaboration, AI, service provider, and critical infrastructure, and emerging solutions, to domestic and foreign organizations across all industry segments. Its solutions leverage a broad range of professional, consultative, and managed services across the technology spectrum. The company possesses top-level engineering certifications with a broad range of IT technologies that enable the company to offer multi-vendor IT solutions that are optimized for each of its customers' specific requirements. It also offers a wide portfolio of technology and other capital asset financing solutions to customers across commercial and government enterprises, designing programs.

About MLYS Mineralys Therapeutics Inc.

Mineralys Therapeutics Inc is a biopharmaceutical company focused on developing medicines to target diseases driven by dysregulated aldosterone. The Company's product candidate, lorundrostat, is a proprietary, orally administered, aldosterone synthase inhibitor that the Company is developing for the treatment of cardiorenal conditions affected by dysregulated aldosterone, including hypertension and related comorbidities, such as chronic kidney disease and obstructive sleep apnea. Its product candidate, lorundrostat, is a proprietary, orally administered, selective ASI that is designed to reduce aldosterone levels by inhibiting CYP11B2, the enzyme responsible for producing the hormone.

Share on Social Networks: